Geron Corp. buy klostergang
Start price
26.06.15
/
50%
€3.58
Target price
07.12.15
€4.50
Performance (%)
29.46%
End price
07.12.15
€4.63
Summary
This prediction ended on 07.12.15 with a price of €4.63. The BUY prediction by klostergang finished with a performance of 29.46%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | -9.990% | -9.990% | 3.452% | -41.272% |
| iShares Core DAX® | -1.741% | 5.666% | 7.839% | 50.715% |
| iShares Nasdaq 100 | 2.815% | 11.547% | 36.610% | 102.822% |
| iShares Nikkei 225® | -0.109% | 9.654% | 45.650% | 64.795% |
| iShares S&P 500 | 0.966% | 7.240% | 26.969% | 70.251% |
Comments by klostergang for this prediction
In the thread Geron Corp. diskutieren
Mit JNJ-Partnerschaft und Orphan Drug der FDA gegen Krebs :
Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.
(Vom Mitglied beendet)


